Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge ...

Polycythemia vera is a classic myeloproliferative neoplasm and a chronic type of leukemia, which often leads to ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have ...

We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...

Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

The first phase 3 trial of the injectable hepcidin mimetic, called VERIFY, has met all its primary and secondary objectives, ...

An experimental medicine from Protagonist Therapeutics stabilized red blood cells and improved symptoms in patients with a ...

Rusfertide outperformed placebo in polycythemia vera, meeting all primary and secondary end points in the phase 3 VERIFY ...

Topline data were announced from a phase 3 trial evaluating rusfertide in patients with polycythemia vera (PV). The 3-part, randomized, ...

Ionis’ drug, called sapablursen, is currently being tested in a Phase 2 trial in people with polycythemia vera.